Best Peptides for Weight Loss in 2026: An Evidence-Based Ranking

How this ranking works

"Best" for weight loss depends on what you weight most heavily — magnitude of weight loss, quality of evidence, safety record, regulatory status, or accessibility. This ranking prioritizes evidence quality and demonstrated weight-loss magnitude in humans, because for weight loss specifically, there is now a deep clinical evidence base — and compounds without that evidence shouldn't be ranked alongside compounds that have it.

Nothing here is medical advice. These are descriptions of what the research shows. Decisions about weight-loss therapy belong with a qualified clinician.

#1: Tirzepatide

Evidence: Strong (FDA-approved) · Weight loss: ~21%

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist and currently the deepest FDA-approved weight-loss medication. In the SURMOUNT-1 trial, participants lost approximately 21% of body weight at 72 weeks on the 15 mg dose. The SURMOUNT-5 head-to-head trial confirmed tirzepatide produces greater weight loss than semaglutide.

The dual-agonist mechanism — activating both GLP-1 and GIP receptors — is what makes it deeper than GLP-1 mono-agonists. For pure weight-loss magnitude among approved options, tirzepatide leads.

Best for: Maximum approved weight-loss magnitude. Watch: The cardiovascular outcomes trial (SURPASS-CVOT) is still pending, so the long-term hard-endpoint evidence is less complete than semaglutide's.

#2: Semaglutide

Evidence: Strong (FDA-approved) · Weight loss: ~15%

Semaglutide (Ozempic for diabetes, Wegovy for obesity, Rybelsus oral) is a GLP-1 receptor agonist and the most-studied weight-loss peptide in modern medicine. The STEP-1 trial showed ~15% mean weight loss at 68 weeks.

What earns semaglutide the #2 spot despite less weight loss than tirzepatide is its cardiovascular evidence. The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease — the first cardiovascular outcomes trial for an obesity indication. The FLOW trial extended the evidence to kidney outcomes.

Best for: Obesity with cardiovascular disease, where the hard-outcomes evidence matters most. Also the only option with an oral formulation (Rybelsus).

#3: Retatrutide

Evidence: Promising (Phase 3 ongoing) · Weight loss: ~24% (Phase 2)

Retatrutide is Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data showed approximately 24% mean weight loss at 48 weeks — deeper than tirzepatide. The third receptor arm (glucagon) adds energy expenditure and direct liver-fat effects.

Retatrutide isn't FDA-approved yet; the Phase 3 TRIUMPH program is ongoing with readouts expected through 2026 and likely approval in 2026-2027. If the Phase 2 magnitude holds, it would become the deepest weight-loss agent available.

Best for: A future option to watch — not something you can access outside trials today.

#4: Cagrilintide and CagriSema

Evidence: Promising (Phase 3 ongoing) · Weight loss: 20%+ (in combination)

Cagrilintide is a long-acting amylin analog. Amylin is a peptide hormone co-secreted with insulin that contributes to satiety through pathways distinct from GLP-1. The strategy that makes cagrilintide interesting is combination: CagriSema (cagrilintide + semaglutide) pairs two complementary appetite-regulation mechanisms.

Phase 2 data showed the combination produces additive weight loss over semaglutide alone. The Phase 3 REDEFINE program is ongoing. If approved, CagriSema would be one of the first fixed-combination obesity medications.

Best for: Watching the combination paradigm develop. Pramlintide — the older, FDA-approved amylin analog — is available now but requires three-times-daily injection.

#5: Liraglutide

Evidence: Strong (FDA-approved) · Weight loss: ~6-8%

Liraglutide (Saxenda for obesity, Victoza for diabetes) was the first widely-used GLP-1 weight-loss medication. It produces less weight loss than semaglutide or tirzepatide — typically 6-8% — and requires daily rather than weekly injection.

It still ranks because it has specific advantages: a longer real-world track record, a pediatric obesity indication, a faster washout if therapy needs to stop quickly (for surgery or pregnancy planning), and daily dosing that allows finer titration adjustment.

Best for: Specific clinical situations (pediatric, pre-surgical, rapid-washout needs) rather than maximum weight-loss magnitude.

#6: Tesamorelin

Evidence: Strong for a narrow indication · Visceral-fat-specific

Tesamorelin is a GHRH analog FDA-approved specifically for reducing visceral (abdominal) fat in HIV-associated lipodystrophy. It is the only peptide with FDA approval explicitly for visceral fat reduction.

It doesn't belong in the same conversation as GLP-1s for general weight loss — it's not approved for that, and the magnitude of overall weight loss is modest. But for the specific goal of reducing visceral adiposity (the metabolically dangerous abdominal fat), it has a unique evidence base. It's sometimes discussed in combination with GLP-1s for visceral-fat-focused protocols.

Best for: Visceral-fat-specific concerns, typically as a clinician-directed adjunct rather than a primary weight-loss agent.

What about research-grade "fat loss" peptides?

Several research-grade peptides are marketed for weight loss in biohacker communities. Honest assessment:

AOD-9604 — a fragment of growth hormone marketed for fat loss. Its clinical development was halted in 2007 after Phase 2 trials didn't meet weight-loss endpoints. The marketing substantially outruns the evidence.

5-Amino-1MQ — an NNMT inhibitor with interesting preclinical adipose-tissue effects in rodents. No human clinical trial data for weight-loss endpoints.

MOTS-c — a mitochondrial-derived peptide with metabolic effects in animal models. No human weight-loss trials.

Tesofensine — not a peptide (a small-molecule triple monoamine reuptake inhibitor), sometimes discussed in the same context. Has some clinical weight-loss data but a stimulant-class side-effect profile.

The honest framing: none of the research-grade peptides has weight-loss evidence remotely comparable to the GLP-1-class drugs. If weight loss is the goal and you want evidence behind the choice, the approved GLP-1-class options are the answer.

What to avoid

A few compounds circulate in weight-loss discussions that warrant explicit caution:

• DNP (2,4-dinitrophenol) — not a peptide, but appears in extreme fat-loss discussions. Causes fatal hyperthermia; documented deaths. Never use.
• Adipotide — a peptidomimetic with dramatic rodent fat-loss data but renal toxicity that halted clinical development. Appears in grey-market channels; safety in humans is poorly characterized.
• Unverified compounded or grey-market GLP-1s — the molecule may be legitimate, but identity, purity, and dosing accuracy from unverified sources are documented problems. See our article on compounded semaglutide.

The honest bottom line

For weight loss in 2026, the evidence-based answer is clear: the GLP-1-class drugs and their relatives. Tirzepatide for maximum magnitude, semaglutide for the cardiovascular evidence, retatrutide and CagriSema as the next wave. The research-grade peptides marketed for fat loss have not earned a place in that conversation on the evidence.

The most effective approach pairs whichever medication fits your clinical situation with the behavioral foundation — resistance training, adequate protein, structured eating — that determines body composition and long-term durability. The medication does the heavy lifting on appetite; the habits determine what the outcome looks like and whether it lasts.